Younger patients with remitted primary anterior uveitis are at a higher risk of relapsing

Article

Young adults with remitted primary anterior uveitis pose a higher risk of relapsing than middle-aged adults.

Young adults with remitted primary anterior uveitis pose a higher risk of relapsing than middle-aged adults, according to an investigation featured in Ophthalmology.

Dr John H. Kempen et al., Department of Ophthalmology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA, compiled a retrospective cohort study on 102 anterior uveitis patients. Each patient achieved remission during the primary episode of anterior uveitis within 90 days of diagnosis. Information was obtained via a standardized chart review and the main outcome measures included time to relapse of anterior uveitis and the risk factors contributing towards relapse.

The findings demonstrated a recurrence of anterior uveitis in 40 patients and a relapse incidence in 24% per patient, per year. Of the patients studied, 61% remained in remission at 1.5 years after remission.

The comparison of 18–35 year old patients with 35–55 year old patients revealed that younger adults presented with a significantly higher relapse risk than middle-aged adults.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.